Estimated economic costs of overactive bladder in the United States. - Wikidata - wikimedia - TriplyDB

Estimated economic costs of overactive bladder in the United States.

Estimated economic costs of overactive bladder in the United States.

http://www.wikidata.org/entity/Q46914426

about

Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults Anticholinergic drugs versus other medications for overactive bladder syndrome in adults Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults Overview of the Epidemiology of Lower Urinary Tract Dysfunction in South Korea Pharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladder Trospium chloride treatment of overactive bladder Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence Prevalence, evaluation and management of overactive bladder in primary care Macrovascular Complications and Prevalence of Urgency Incontinence in Japanese Patients with Type 2 Diabetes Mellitus: The Dogo Study.Progression of lower urinary tract symptoms in older men: a community based study.Benign Prostatic Hyperplasia and Male Lower Urinary Tract Symptoms: Epidemiology and Risk Factors.Lifestyle and health factors associated with progressing and remitting trajectories of untreated lower urinary tract symptoms among elderly men.Observational study: daily treatment with a new compound "Tradamixina" plus serenoa repens for two months improved the lower urinary tract symptoms.Darifenacin: a muscarinic M3-selective receptor antagonist for the treatment of overactive bladder.Crucial role of TRPC1 and TRPC4 in cystitis-induced neuronal sprouting and bladder overactivity.The effects of acute and chronic psychological stress on bladder function in a rodent model.Darifenacin: a novel M3 muscarinic selective receptor antagonist for the treatment of overactive bladder.Prevalence and Clinical Features of Detrusor Underactivity among Elderly with Lower Urinary Tract Symptoms: A Comparison between Men and Women.Psychometric Properties of the Korean Version of the Overactive Bladder Questionnaire (OAB-q) in a Korean Population.Tolterodine for the treatment of overactive bladder: a review.Overactive bladder.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trials The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Cost implications of antimuscarinic drugs in the treatment of overactive bladder syndrome.Absolute bioavailability of imidafenacin after oral administration to healthy subjects Current and emerging investigational medical therapies for the treatment of overactive bladder.The Burden of Overactive Bladder on US Public Health Intradetrusor botulinum toxin type A in refractory overactive bladder: A potential future treatment.Pharmacologic management of overactive bladder.Cost-effectiveness of a behavioral intervention for persistent urinary incontinence in prostate cancer patients.Diagnosis and office-based treatment of urinary incontinence in adults. Part one: diagnosis and testing Tolterodine for the treatment of overactive bladder.Women's experience with severe overactive bladder symptoms and treatment: insight revealed from patient focus groups.Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: Single center experience Role of fesoterodine in the treatment of overactive bladder.Social, economic, and health utility considerations in the treatment of overactive bladder.Characterization of overactive bladder in women in a primary care setting Tolterodine extended release is well tolerated in older subjects Oxybutynin extended release for the management of overactive bladder: a clinical review.Fesoterodine for the treatment of urinary incontinence and overactive bladder.

P2860

Q24202075-64E9B7A9-B1D2-4D95-BBFC-932D5310B2A2 Q24243527-E4948DFA-04A7-4916-BFA7-62F485343A93 Q24243956-0E4BF575-1630-4C43-951C-161CF8ABC4FD Q26744685-B5414BF9-FCF6-4734-B849-1B9DA8EA8B93 Q28275473-7B760F69-011C-4BE6-808E-5B851B6F093F Q28308162-20F6F9DC-A356-472C-B6B5-B6E954DAC269 Q30906698-EBE158AC-DDBF-4B97-BCAD-FB95BAD89E84 Q33402658-CE4FFFA5-F7FB-4D31-B8C6-0020DF57DFB6 Q33781106-CDA3F818-D968-48B3-9307-85CE43E1E61A Q33958191-935BA166-FADA-4D66-8397-A03DE8B6D676 Q34176834-B25E2E14-CB3C-4F2A-879A-C8C99F96F5CC Q34425753-BFC8A54B-B2D3-454F-A66E-6FF2CD1D9ED3 Q34485602-8C6679D0-D31D-4FFE-8AF0-A740AE35D15B Q34575850-AC68893D-0EE0-4ADA-A161-9EEA39DBDF40 Q34902996-303A3F01-4A00-4DB5-AAE6-0FDB0606E9A9 Q35301066-02E8F47A-1421-4B1D-84D9-0A1C5202D5F8 Q35925590-FD247E4E-CA57-4244-82F3-1CD89A5E10C2 Q35999333-F52C9F0E-986A-4129-8488-48A83626922D Q36092237-9905B528-74B0-4D36-8173-1446FF010B6F Q36150735-CBD9B499-EAEE-4D2C-82C0-0F7F56E0EA1B Q36226387-49EC6B74-E612-47A5-B220-36AA579F3F2F Q36307893-6384F4B4-BA03-48C8-87F2-889F52E9AD4F Q36428471-68B09673-D0F9-4B8F-B12C-BBD1781F20A3 Q36428481-649C95CF-30C6-496D-B29E-93F5497D60D2 Q36535862-69645DB2-A908-42BE-85D4-BC4A443129B4 Q36568728-0B7B77A5-6540-49F0-9121-C26F4234032C Q36767014-9D38E3E8-6386-49AD-851A-C6D1FCA7C385 Q36855832-6136E605-033F-41D9-BBA6-62C5C73D43D8 Q37017434-342E446E-1CA0-4483-8912-7BE3C9056760 Q37035899-267F5DDF-5B84-4CE5-A5C2-BCD8B0DA0CBB Q37040764-12793661-7377-4559-AEFD-64C24EA9CAC5 Q37142090-741E39D2-ED91-4A6C-A353-139EEAB866C5 Q37156783-9FBCBF58-BB8B-4CEA-A3BE-F68A0E196428 Q37197554-DB48082F-FEB5-487B-A21A-D3C0738E8300 Q37283542-56E20627-1C33-4AD9-861A-BF07C584B40D Q37283547-14A60ED6-1922-4B87-B016-20FECE9F201B Q37283712-6C692CB5-5446-4E34-B6BD-F6CB6B51B562 Q37332901-C23F23FE-D6F4-4E44-8CB5-81ADB4309B1C Q37403203-A3536059-B2A7-40B6-B618-94D93D088684 Q37429813-20640330-02FC-4190-A371-177AE8654CA9

P2860

Estimated economic costs of overactive bladder in the United States.

http://www.wikidata.org/entity/Q46914426

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年学术文章

@wuu

2003年学术文章

@zh

2003年学术文章

@zh-cn

2003年学术文章

@zh-hans

2003年学术文章

@zh-my

2003年学术文章

@zh-sg

2003年學術文章

@yue

2003年學術文章

@zh-hant

name

Estimated economic costs of overactive bladder in the United States.

@en

Estimated economic costs of overactive bladder in the United States.

@nl

type

label

Estimated economic costs of overactive bladder in the United States.

@en

Estimated economic costs of overactive bladder in the United States.

@nl

prefLabel

Estimated economic costs of overactive bladder in the United States.

@en

Estimated economic costs of overactive bladder in the United States.

@nl

P1433

Q46914426-3B07A32C-B842-4A72-8274-E5987A84363C

P1476

Q46914426-84EBAD42-A24C-4957-89A6-F51B335746E8

P2093

Q46914426-16D80851-0113-4FCC-8F34-612AC0F506EC

Q46914426-2B7526AF-8FD3-4D84-8A16-66CAE9958051

Q46914426-446C7C4B-5665-491F-AB3A-AD47DD056321

Q46914426-525F49EB-BAAD-40D7-81E6-7C012E265012

Q46914426-537D7052-8A86-4ED7-A37F-62A287B848EB

Q46914426-5AA57D9A-BE37-4AB3-8207-35EA9E84CE36

Q46914426-7AB97C8A-3C73-4917-92A7-C8E9D3A20A7A

Q46914426-D90CE20E-2D5B-4B61-AC75-007EE1B48A74

Q46914426-E341418A-C85A-4BD0-B870-1359EF6BF33D

P304

Q46914426-0EA4DFE9-19ED-4DE2-A87C-55EC5FE934D3

P31

Q46914426-152ED3C7-0DEA-4401-9848-98E713E2959F

P356

Q46914426-1220B744-534A-4EDF-B00F-80E76E3BE4DE

P407

Q46914426-A0B994B7-B42B-4DC8-830A-B1448F183CC9

P433

Q46914426-D6D1C74B-0C9A-45A4-A23B-BE82ADB00471

P478

Q46914426-4F4ACFE3-5BD3-430E-9F9E-A6F46FE615B5

P577

Q46914426-74E07AED-D933-46B8-97F7-7362A0817EA6

P698

Q46914426-A7A2513C-10D8-4211-93D0-2CE017AD9543

P921

Q46914426-1CA5403C-B290-495C-B7A0-79F5424A680B

P356

S0090-4295(03)00009-8

P1433

P1476

Estimated economic costs of overactive bladder in the United States.

@en

P2093

Amy Piancentini

http://www.w3.org/2001/XMLSchema#string

Judith D Bentkover

http://www.w3.org/2001/XMLSchema#string

Kristi LeBlanc

http://www.w3.org/2001/XMLSchema#string

Ron Corey

http://www.w3.org/2001/XMLSchema#string

Steve Z Zhou

http://www.w3.org/2001/XMLSchema#string

Teh-Wei Hu

http://www.w3.org/2001/XMLSchema#string

Timothy L Hunt

http://www.w3.org/2001/XMLSchema#string

Todd H Wagner

http://www.w3.org/2001/XMLSchema#string

Walter F Stewart

http://www.w3.org/2001/XMLSchema#string

P304

1123-1128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/S0090-4295(03)00009-8

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

61

http://www.w3.org/2001/XMLSchema#string

P577

2003-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12809878

http://www.w3.org/2001/XMLSchema#string

P921

Ameeriga Ütisriigiq